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documentation of the searches is crucial to ensure the best possible acceptance of 
evidence in the AMNOG process.
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Objectives: Currently there is no formal HTA agency in Russia, although the need 
for HTA as an evidence tool for policy makers is increasing due to budget constraints. 
However, there are HTA bodies which to some extent influence decison makers 
through publications of pharmacoeconomic studies. The objective of the present 
study was to gain insights into the current activities of existing HTA organizations 
and research trends in developing HTA in Russia. MethOds: A manual search of 
four Russian HTA organizations’ websites was conducted to find pharmacoeco-
nomic assessments published from 1998 onwards. Per agency, all relevant reports 
were categorized by therapeutic area and publication date. Any revealed patterns 
in the HTA topics were in-depth analyzed and compared with the World Health 
Organization (WHO) country profile of Russia. Results: In total, 180 pharmaco-
economic assessments published by four Russian HTA organizations were identi-
fied. Overall, the majority of studies were performed in cardiovascular (n= 45; 25%) 
and oncology (n= 32; 18%) disease areas, which are according to the WHO, the two 
leading causes of death, both in Russia and globally. The total number of pharma-
coeconomic publications per year has been constantly increasing from one study in 
1998 to 26 in 2009, however with fewer reports published in 2010-2013 (32 HTAs in 
three years). When reported, the potential willingness-to-pay (WTP) threshold for 
cost-effectiveness was suggested to be 3*Gross Domestic Product (GDP) per capita 
as recommended by WHO, which equals to approximately 30,000 euro per Quality 
Adjusted Life Year (QALY) gained. cOnclusiOns: Although formally Russia does 
not have a transparent HTA based reimbursement process, existing HTA organiza-
tions are constantly developing and gaining HTA experience by conducting assess-
ments in the therapeutic areas with the highest burden on Russian population. 
These areas of interest, as well as an approach to define WTP threshold, match with 
WHO data and recommendations.
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Objectives: Requirements for systematic literature reviews (SLRs) within a 
Health Technology Assessment (HTA) submission vary across the world. The objec-
tive of this study is to compare clinical and economic SLR requirements issued 
by eight HTA agencies in the UK (England and Wales, Wales, Scotland), Ireland, 
Germany, Sweden, Canada, and Australia. MethOds: SLR requirements issued by 
the National Institute for Health and Care Excellence (NICE), All Wales Medicines 
Strategy Group (AWMSG), Scottish Medicines Consortium (SMC), National Centre 
for Pharmacoeconomics (NCPE), Gemeinsamer Bundesausschuss (G-BA) (Federal 
Joint Committee), The Dental and Pharmaceutical Benefits Agency (TLV), Canadian 
Agency for Drugs and Technologies in Health (CADTH), and Pharmaceutical Benefits 
Advisory Committee (PBAC) were compared, and a checklist of requirements was 
compiled. Results: SLRs of the clinical and economic evidence underpin the HTA 
process. However, HTA agencies vary on the specific requirements for each and the 
need for critical appraisal of identified clinical studies and economic analyses. NICE 
requirements are the most prescriptive, whereas AWMSG and TLV have few stated 
SLR requirements. All agencies require a clinical SLR, although AWMSG does not 
specify outright but requires a clinical SLR to determine economic model inputs. 
Four agencies require both a clinical SLR and critical appraisal of the included stud-
ies (NICE, NCPE, G-BA, and PBAC), although recommended appraisal tools vary. NICE 
and CADTH require both an SLR and a critical appraisal of existing economic evalu-
ations for the intervention of interest; PBAC requires an SLR of only economic evalu-
ations. NICE, SMC, AWMSG, and NCPE require an SLR of utility data, and only NICE 
and SMC specify the need for an SLR of cost and resource use data. A more detailed 
analysis of specific methodology requirements will be presented. cOnclusiOns: 
Although SLR requirements vary between HTA agencies, a clinical SLR is a key 
requirement for all eight agencies investigated.
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Objectives: To assess the level of transparency of health technology assessment 
(HTA) organizations in eight countries (Australia, Canada, Brazil, France, Germany, 
Italy, Spain, and the UK). MethOds: Nine national review bodies carrying out HTAs 
for the purposes of reimbursement and funding decisions within their respective 
countries were assessed according to 33 transparency parameters. The parameters 
were designed to assess the level of transparency in the HTA processes, clinical and 
economic reviews, and stakeholder involvement. Using a modified Delphi process, 
each parameter was weighted based on its importance to transparency and given a 
score from one to ten. A review of each national body was conducted to determine 
whether or not they included each of the 33 parameters. Data from public sources 
(i.e., organization websites) were utilized and interviews with international experts 
were conducted to verify the information. Total scores were calculated and con-
verted to a transparency index, with 100% being the most transparent. The score was 
adjusted for review bodies that did not require economic evaluations for their HTA 
process. Results: The level of transparency varies greatly amongst the HTA organi-
Objectives: In Australia, the decision process for the reimbursement of orphan 
drugs on the Life-Saving Drugs Program (LSDP) is centred on a drug’s ability to 
meet strict criteria as specified and assessed by both the Pharmaceutical Benefits 
Advisory Committee (PBAC) and the LSDP Advisory Committees. The objective of this 
research was to investigate the key determinants of PBAC decisions with respect to 
the LSDP criteria in order to understand the key challenges facing new treatments 
seeking LSDP funding. MethOds: A systematic search was conducted of all avail-
able Public Summary Documents (PSDs) from July 2005 to April 2013, to identify 
products that have sought listing on the LSDP. The selected PSDs were reviewed 
and data extracted according to categories defined by the LSDP criteria. Data were 
then qualitatively analysed within and across categories to identify key themes 
and concepts influencing decisions. Quantitative analyses were also conducted on 
the number of submissions, rejections, deferrals and the time from when a product 
first sought reimbursement to when funding was initiated. Results: Since the 
LSDP was created in 1995 only 12 products have sought LSDP funding, 10 are cur-
rently reimbursed covering 7 disease areas. Of the applications reviewed, 58% of 
submissions were immediately referred from the PBAC to LSDP for funding, 17% 
were initially rejected and after subsequent submissions have been funded, and 
25% of applications are yet to receive funding. The average time from the first PBAC 
consideration of a product until funding on the LSDP is 19.7months. The most com-
mon reason for rejection was around uncertainty in a drug’s ability to significantly 
prolong life and the appropriateness of surrogate outcomes to accurately predict 
long-term survival. cOnclusiOns: This analysis shows there is a pathway to reim-
bursement of high cost orphan drugs when there is a reasonable level of evidence 
supporting survival gains.
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Objectives: In the UK, NICE assesses health technologies based on clinical 
and cost-effectiveness evidence. Recommendations ensure NHS patients have 
access to the most clinically effective treatments, whilst using NHS resources 
cost-effectively. Nevertheless, cost-effectiveness analyses are susceptible to limi-
tations which make the true value of a technology uncertain. This study investi-
gates what other factors NICE considers when making recommendations under 
uncertainty. MethOds: All Single Technology Appraisals (STAs) published by NICE 
between 2011-2013 inclusive were reviewed. Recommendations were identified 
as being made under uncertainty if there was a less than 50% probability that the 
intervention was cost-effective at a willingness-to-pay threshold of £20,000 per 
QALY gained. NICE committee reports for these appraisals were reviewed to deter-
mine the factors taken into account when making a recommendation. Results: 
Of 64 STAs published in the studied period, 31 interventions were identified with 
uncertainty at the willingness-to-pay threshold of £20,000, of which 18 (58%) were 
recommended by NICE. Moreover, only 4 (22%) recommended STAs with uncer-
tainty at £20,000 had a greater than 50% probability of being cost-effective at a 
threshold of £30,000. Of the STAs recommended under uncertainty, 13 (72%) had a 
patient access scheme (PAS) in place, while 3 (17%) fulfilled end-of-life treatment 
criteria. Health-related benefits not captured in the manufacturer’s economic 
model that were likely to lower the ICER, innovative technologies, or interven-
tions satisfying an unmet clinical need were also taken into account. For exam-
ple, fingolimod was recommended by NICE for treatment of multiple sclerosis 
based on its oral rather than intravenous formulation and because benefits from 
a reduced caregiving need were not accounted for in the manufacturer’s economic 
model. cOnclusiOns: Even under uncertainty, NICE often recommends new 
technologies, particularly if a PAS is in place or if additional costs are deemed to 
be justified by the benefit provided to patients or their families.
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Objectives: The benefit assessment of new drugs in Germany requires the sub-
mission of a value dossier including systematic searches. The majority of dossiers 
are methodically inspected and assessed by the German Institute for Quality and 
Efficiency in Healthcare (IQWiG). The study’s objective was the analysis of com-
mon deficiencies in systematic searches and their consequences for the IQWiG 
assessment. MethOds: A total of 37 IQWiG assessment reports were analysed 
with regard to all comments made on the presented systematic searches in the 
dossier of the pharmaceutical company. A distinction was made between literature 
and study searches. The respective IQWiG comments were categorized and listed. 
Inadequate searches were examined in terms of consequences for the assessment 
by the IQWiG. Consequences were divided into those affecting the search required 
for the substance itself and those carried out for indirect comparisons/ further 
investigations. Results: A total of 4 of the 37 dossiers passed the IQWiG assess-
ment without deficiencies. Out of all analysed searches a total of 104 deficiencies 
were found, of which the most frequent ones referred to the search strings (32%) and 
the documentation of the search (25%). In the consistency check on the number of 
hits deviations were found by the IQWiG in 13%; 92% of the inconsistencies occurred 
in study-registry versus 8% in literature searches. There were no consequences in 
62% (23/37) for the substance-search and in 22% (8/37) for indirect comparisons/ 
further investigations. Non-consideration of study results, which was the most 
frequent consequence of an inadequate search, occurred in 24% for the substance-
search and in 32% for indirect comparisons/further analyses. cOnclusiOns: The 
methodological requirements for systematic searches to be accepted by the IQWiG 
are not achieved in the majority of dossiers. An adequate design and a careful 
